Literature DB >> 24879579

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors.

Kim S Bull1, Colin R Kennedy, Simon Bailey, David W Ellison, Steven C Clifford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24879579      PMCID： PMC4313076          DOI： 10.1007/s00401-014-1300-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  11 in total

1.  Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.

Authors:  David W Ellison; Mehmet Kocak; James Dalton; Hisham Megahed; Meryl E Lusher; Sarra L Ryan; Wei Zhao; Sarah Leigh Nicholson; Roger E Taylor; Simon Bailey; Steven C Clifford
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Profile of daily life in children with brain tumors: an assessment of health-related quality of life.

Authors:  Sundeep R Bhat; Tress L Goodwin; Tasha M Burwinkle; Meagan F Lansdale; Gary V Dahl; Stephen L Huhn; Iris C Gibbs; Sarah S Donaldson; Ruth K Rosenblum; James W Varni; Paul G Fisher
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Subgroup-specific localization of human medulloblastoma based on pre-operative MRI.

Authors:  Annika K Wefers; Monika Warmuth-Metz; Julia Pöschl; André O von Bueren; Camelia-Maria Monoranu; Klaus Seelos; Aurelia Peraud; Jörg-Christian Tonn; Arend Koch; Torsten Pietsch; Christel Herold-Mende; Christian Mawrin; Antoinette Schouten-van Meeteren; Dannis van Vuurden; Katja von Hoff; Stefan Rutkowski; Stefan M Pfister; Marcel Kool; Ulrich Schüller
Journal:  Acta Neuropathol       Date:  2014-04-04       Impact factor: 17.088

4.  Functional recovery of children and adolescents after cerebellar tumour resection.

Authors:  Jürgen Konczak; Beate Schoch; Albena Dimitrova; Elke Gizewski; Dagmar Timmann
Journal:  Brain       Date:  2005-01-19       Impact factor: 13.501

5.  DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies.

Authors:  Edward C Schwalbe; Daniel Williamson; Janet C Lindsey; Dolores Hamilton; Sarra L Ryan; Hisham Megahed; Miklós Garami; Peter Hauser; Bożena Dembowska-Baginska; Danuta Perek; Paul A Northcott; Michael D Taylor; Roger E Taylor; David W Ellison; Simon Bailey; Steven C Clifford
Journal:  Acta Neuropathol       Date:  2013-01-05       Impact factor: 17.088

6.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.

Authors:  David W Ellison; James Dalton; Mehmet Kocak; Sarah Leigh Nicholson; Charles Fraga; Geoff Neale; Anna M Kenney; Dan J Brat; Arie Perry; William H Yong; Roger E Taylor; Simon Bailey; Steven C Clifford; Richard J Gilbertson
Journal:  Acta Neuropathol       Date:  2011-01-26       Impact factor: 17.088

7.  Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG).

Authors:  Kim S Bull; Helen A Spoudeas; Ghasem Yadegarfar; Colin R Kennedy
Journal:  J Clin Oncol       Date:  2007-09-20       Impact factor: 44.544

8.  Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma.

Authors:  Colin Kennedy; Kim Bull; Mathilde Chevignard; David Culliford; Helmuth G Dörr; François Doz; Rolf-Dieter Kortmann; Birgitta Lannering; Maura Massimino; Aurora Navajas Gutiérrez; Stefan Rutkowski; Helen A Spoudeas; Gabriele Calaminus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-13       Impact factor: 7.038

9.  Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study.

Authors:  Shawna L Palmer; Carol Armstrong; Arzu Onar-Thomas; Shengjie Wu; Dana Wallace; Melanie J Bonner; Jane Schreiber; Michelle Swain; Lynn Chapieski; Donald Mabbott; Sarah Knight; Robyn Boyle; Amar Gajjar
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

10.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088
View more
  4 in total

1.  Quality of life in long-term survivors treated for metastatic medulloblastoma with a hyperfractionated accelerated radiotherapy (HART) strategy.

Authors:  L Veneroni; L Boschetti; F Barretta; C A Clerici; F Simonetti; E Schiavello; V Biassoni; F Spreafico; L Gandola; E Pecori; B Diletto; G Poggi; F Gariboldi; R Sensi; M Massimino
Journal:  Childs Nerv Syst       Date:  2017-08-02       Impact factor: 1.475

2.  Multidisciplinary Management of Medulloblastoma: Consensus, Challenges, and Controversies.

Authors:  Abhishek Chatterjee; Madan Maitre; Archya Dasgupta; Epari Sridhar; Tejpal Gupta
Journal:  Methods Mol Biol       Date:  2022

3.  A comparison of self-reported and proxy-reported health utilities in children: a systematic review and meta-analysis.

Authors:  Aixia Ma; Pingyu Chen; Mingyu Jiang; Yue Ma; Minghui Li; Rui Meng
Journal:  Health Qual Life Outcomes       Date:  2021-02-05       Impact factor: 3.186

4.  Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort.

Authors:  Cynthia B de Medeiros; Iska Moxon-Emre; Nadia Scantlebury; David Malkin; Vijay Ramaswamy; Alexandra Decker; Nicole Law; Toshihiro Kumabe; Jeffrey Leonard; Josh Rubin; Shin Jung; Seung-Ki Kim; Nalin Gupta; William Weiss; Claudia C Faria; Rajeev Vibhakar; Lucie Lafay-Cousin; Jennifer Chan; Johan M Kros; Laura Janzen; Michael D Taylor; Eric Bouffet; Donald J Mabbott
Journal:  Cancer Med       Date:  2019-11-21       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.